These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15993586)

  • 1. Identification of novel angiogenesis inhibitors.
    Sridhar J; Akula N; Sivanesan D; Narasimhan M; Rathinavelu A; Pattabiraman N
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4125-9. PubMed ID: 15993586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-silico fragment-based identification of novel angiogenesis inhibitors.
    Dakshanamurthy S; Kim M; Brown ML; Byers SW
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4551-6. PubMed ID: 17591441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery of novel vascular endothelial growth factor receptor tyrosine kinases inhibitors: pharmacophore modeling, virtual screening and docking studies.
    Yu H; Wang Z; Zhang L; Zhang J; Huang Q
    Chem Biol Drug Des; 2007 Mar; 69(3):204-11. PubMed ID: 17441906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.
    Kuo GH; Wang A; Emanuel S; Deangelis A; Zhang R; Connolly PJ; Murray WV; Gruninger RH; Sechler J; Fuentes-Pesquera A; Johnson D; Middleton SA; Jolliffe L; Chen X
    J Med Chem; 2005 Mar; 48(6):1886-900. PubMed ID: 15771433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors.
    Peifer C; Selig R; Kinkel K; Ott D; Totzke F; Schächtele C; Heidenreich R; Röcken M; Schollmeyer D; Laufer S
    J Med Chem; 2008 Jul; 51(13):3814-24. PubMed ID: 18529047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adrenomedullin stimulates angiogenic response in cultured human vascular endothelial cells: involvement of the vascular endothelial growth factor receptor 2.
    Guidolin D; Albertin G; Spinazzi R; Sorato E; Mascarin A; Cavallo D; Antonello M; Ribatti D
    Peptides; 2008 Nov; 29(11):2013-23. PubMed ID: 18692535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
    Pradeep CR; Sunila ES; Kuttan G
    Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase.
    Piatnitski EL; Duncton MA; Kiselyov AS; Katoch-Rouse R; Sherman D; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4696-8. PubMed ID: 16143524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational design, structure, and biological evaluation of cyclic peptides mimicking the vascular endothelial growth factor.
    Goncalves V; Gautier B; Coric P; Bouaziz S; Lenoir C; Garbay C; Vidal M; Inguimbert N
    J Med Chem; 2007 Oct; 50(21):5135-46. PubMed ID: 17900101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor.
    Mousa SA; Bergh JJ; Dier E; Rebbaa A; O'Connor LJ; Yalcin M; Aljada A; Dyskin E; Davis FB; Lin HY; Davis PJ
    Angiogenesis; 2008; 11(2):183-90. PubMed ID: 18080776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenic response of endothelial cells to heparin-binding domain of fibronectin.
    Viji RI; Kumar VB; Kiran MS; Sudhakaran PR
    Int J Biochem Cell Biol; 2008; 40(2):215-26. PubMed ID: 17766169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
    Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
    J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure and anti-proliferation function of 5,5-diphenyl-2-thiohydantoin (DPTH) derivatives in vascular endothelial cells.
    Cheng CK; Wu J; Liu Y; Lee TS; Kang SJ; Sheu MT; Lee WS
    Vascul Pharmacol; 2008; 48(2-3):138-42. PubMed ID: 18295547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-angiogenic action of plasma hyaluronan binding protein in human umbilical vein endothelial cells.
    Jeon JW; Song HS; Moon EJ; Park SY; Son MJ; Jung SY; Kim JT; Nam DH; Choi-Miura NH; Kim KW; Kim YJ
    Int J Oncol; 2006 Jul; 29(1):209-15. PubMed ID: 16773202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
    La DS; Belzile J; Bready JV; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn JC; Flynn SR; Graceffa RF; Harriman SP; Larrow JF; Long AM; Martin MW; Morrison MJ; Patel VF; Roveto PM; Wang L; Weiss MM; Whittington DA; Teffera Y; Zhao Z; Polverino AJ; Harmange JC
    J Med Chem; 2008 Mar; 51(6):1695-705. PubMed ID: 18311900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the tyrosine phosphatase SHP-2 suppresses angiogenesis in vitro and in vivo.
    Mannell H; Hellwig N; Gloe T; Plank C; Sohn HY; Groesser L; Walzog B; Pohl U; Krotz F
    J Vasc Res; 2008; 45(2):153-63. PubMed ID: 17962719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenethyl isothiocyanate inhibits angiogenesis in vitro and ex vivo.
    Xiao D; Singh SV
    Cancer Res; 2007 Mar; 67(5):2239-46. PubMed ID: 17332354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced capillary formation stimulated by a chimeric vascular endothelial growth factor/vascular endothelial growth factor-C silk domain fusion protein.
    Keskitalo S; Tammela T; Lyytikka J; Karpanen T; Jeltsch M; Markkanen J; Yla-Herttuala S; Alitalo K
    Circ Res; 2007 May; 100(10):1460-7. PubMed ID: 17478734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of fractalkine/CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A/KDR and reverses hindlimb ischaemia.
    Ryu J; Lee CW; Hong KH; Shin JA; Lim SH; Park CS; Shim J; Nam KB; Choi KJ; Kim YH; Han KH
    Cardiovasc Res; 2008 May; 78(2):333-40. PubMed ID: 18006432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.